Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Press Announcements

Press Announcements Home
          News & Events
          FDA Newsroom
          Press Announcements
          FDA Roundup: December 5, 2023Press Announcements FDA News Release
  FDA Roundup: December 5, 2023

  
  Share
    Post
    Linkedin

    Email
    PrintFor Immediate Release:
                  December 05, 2023
 

  
      
       

  Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:

Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treatments for rare diseases, as well as the FDA’s efforts to promote new medical products for patients with rare diseases.Free continuing education (CE) credit will be available for eligible health care professionals. See Rare Disease Day 2024 for more information and details on how to register.

On Monday, the FDA published the FDA Voices: “The Importance of Clinical Trial Transparency and FDA Oversight,” by Robert M. Califf, M.D., Commissioner of Food and Drugs. The FDA takes its oversight of clinical trials seriously and encourages voluntary compliance with the ClinicalTrials.gov requirements. We communicate transparency expectations and obligations under the law and use a risk-based approach to prioritize compliance and enforcement actions for the violations that pose the greatest risk to public health. The FDA is committed to promoting clinical trial transparency and will continue to advance our compliance activities related to the ClinicalTrials.gov database.
	On Friday, the FDA granted accelerated approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. The most common adverse reactions (≥ 20%), excluding laboratory terms, were fatigue, bruising, cough, musculoskeletal pain, COVID-19, diarrhea, pneumonia, abdominal pain, dyspnea, hemorrhage, edema, nausea, pyrexia, and headache. View the prescribing information for Jaypirca.
	On December 12-13, 2023, the National Academies of Sciences, Engineering, and Medicine, with the Forum on Drug Discovery, Development and Translation and the Forum on Neuroscience and Nervous System Disorders, will host a virtual public workshop titled, “Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development.”This workshop will provide a venue for professionals who typically diagnose adult attention-deficit/hyperactivity disorder (ADHD), drug developers, researchers, people with lived experience, and other stakeholders to discuss the diagnosis and treatment of adults with ADHD, explore challenges and opportunities for drug development, and consider strategies for assessing the risks and benefits of ADHD medication treatment in adult populations. The workshop is supported, in part, through a grant (PAR-23-072) from the Center for Drug Evaluation and Research at the FDA. Registration is available here.

  Related Information
  
  Related Information
              FDA Newsroom

###
  Boilerplate
      The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
Inquiries
  
    
        
         Media:
                 
      
                            FDA Office of Media Affairs
           
           
                      888-INFO-FDA
    Consumer:
                        888-INFO-FDA

                                                                                  Content current as of:
      12/07/2023
               
               
Regulated Product(s)
		 Biologics
			  			     			  			     Drugs
			     			  			     Medical Devices   

        Follow FDA
            Follow @US_FDAon X
                Follow FDAon Facebook
                Follow @FDAMediaon XMore Press Announcements
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop